Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2011

01-06-2011 | PHASE I STUDIES

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Authors: Joleen Hubbard, Charles Erlichman, David O. Toft, Rui Qin, Bridget A. Stensgard, Sara Felten, Cynthia Ten Eyck, Gretchen Batzel, S. Percy Ivy, Paul Haluska

Published in: Investigational New Drugs | Issue 3/2011

Login to get access

Summary

Purpose: To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of 17-AAG, gemcitabine and/or cisplatin. Levels of the proteins Hsp90, Hsp70 and ILK were measured in peripheral blood mononuclear cell (PMBC) lysates to assess the effects of 17-AAG. Experimental design: Phase I dose-escalating trial using a “3 + 3” design performed in patients with advanced solid tumors. Once the MTD of gemcitabine + 17-AAG + cisplatin was determined, dose escalation of 17-AAG with constant doses of gemcitabine and cisplatin was attempted. After significant hematologic toxicity occurred, the protocol was amended to evaluate three cohorts: gemcitabine and 17-AAG; 17-AAG and cisplatin; and gemcitabine, 17-AAG and cisplatin with modified dosing. Results: The 39 patients enrolled were evaluable for toxicity and response. The MTD for cohort A was 154 mg/m2 of 17-AAG, 750 mg/m2 of gemcitabine, and 40 mg/m2 of cisplatin. In cohort A, DLTs were observed at the higher dose level and included neutropenia, hyperbilirubinemia, dehydration, GGT elevation, hyponatremia, nausea, vomiting, and thrombocytopenia. The MTD for cohort C was 154 mg/m2 of 17-AAG and 750 mg/m2 of gemcitabine, with one DLT observed (alkaline phosphatase elevation) observed. In cohort C, DLTs of thrombocytopenia, fever and dyspnea were seen at the higher dose level. The remaining cohorts were closed to accrual due to toxicity. Six patients experienced partial responses. Mean Hsp90 levels were decreased and levels of Hsp70 were increased compared to baseline. Conclusions: 17-AAG in combination with gemcitabine and cisplatin demonstrated antitumor activity, but significant hematologic toxicities were encountered. 17-AAG combined with gemcitabine is tolerable and has demonstrated evidence of activity at the MTD. The recommended phase II dose is defined as 154 mg/m2 of 17-AAG and 750 mg/m2 of gemcitabine, and is currently being investigated in phase II studies in ovarian and pancreatic cancers. There is no recommended phase II dose for the cisplatin-containing combinations.
Literature
1.
Richter K, Buchner J (2001) Hsp90: chaperoning signal transduction. J Cell Physiol 188(3):281–290PubMedCrossRef
2.
Pratt WB, Toft DO (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228(2):111–133
3.
Goetz MP et al (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14(8):1169–1176PubMedCrossRef
4.
Grenert JP et al (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272(38):23843–23850PubMedCrossRef
5.
Whitesell L et al (1994) Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91(18):8324–8328PubMedCrossRef
6.
Supko JG et al (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36(4):305–315PubMedCrossRef
7.
Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42(4):273–279PubMedCrossRef
8.
Goetz MP et al (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23(6):1078–1087PubMedCrossRef
9.
Solit DB et al (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13(6):1775–1782PubMedCrossRef
10.
Heath EI et al (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14(23):7940–7946PubMedCrossRef
11.
Ronnen EA et al (2006) A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24(6):543–546PubMedCrossRef
12.
Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15(17):2177–2196PubMedCrossRef
13.
Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408(6811):433–439PubMedCrossRef
14.
Rhind N, Russell P (2000) Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J Cell Sci 113(Pt 22):3889–3896PubMed
15.
Zachos G, Rainey MD, Gillespie DA (2003) Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. Embo J 22(3):713–723PubMedCrossRef
16.
Arlander SJ et al (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278(52):52572–52577PubMedCrossRef
17.
McCollum AK et al (2008) Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 7(10):3256–3264PubMedCrossRef
18.
Nair SC et al (1996) A pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor. Cell Stress Chaperones 1(4):237–250PubMedCrossRef
19.
Kim HR, Kang HS, Kim HD (1999) Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 48(4):429–433PubMed
20.
Whitesell L, Bagatell R, Falsey R (2003) The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 3(5):349–358PubMedCrossRef
21.
Winklhofer KF et al (2001) Geldanamycin restores a defective heat shock response in vivo. J Biol Chem 276(48):45160–45167PubMedCrossRef
22.
Bagatell R et al (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6(8):3312–3318PubMed
23.
Nowakowski GS et al (2006) A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12(20 Pt 1):6087–6093PubMedCrossRef
24.
Ramanathan RK et al (2007) Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13(6):1769–1774PubMedCrossRef
25.
McCollum AK, Toft D, Erlichman C (2003) Geldanamycin enhances cisplain cytotoxicty through loss of Akt activation in A549 cells. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, pp 16
26.
Aoyagi Y, Fujita N, Tsuruo T (2005) Stabilization of integrin-linked kinase by binding to Hsp90. Biochem Biophys Res Commun 331(4):1061–1068PubMedCrossRef
27.
Kramer CY (1956) Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12:307–310CrossRef
28.
McCollum AK et al (2008) P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 68(18):7419–7427PubMedCrossRef
29.
Modi S et al (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25(34):5410–5417PubMedCrossRef
30.
Richardson PG, Chanan-Khan A, Lonial S, et al (2007) Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 25(18S):3532, June 20 Supplement
31.
Tse AN et al (2008) A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 14(20):6704–6711PubMedCrossRef
Metadata
Title
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
Authors
Joleen Hubbard
Charles Erlichman
David O. Toft
Rui Qin
Bridget A. Stensgard
Sara Felten
Cynthia Ten Eyck
Gretchen Batzel
S. Percy Ivy
Paul Haluska
Publication date
01-06-2011
Publisher
Springer US
Published in
Investigational New Drugs / Issue 3/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-009-9381-y

Other articles of this Issue 3/2011

Investigational New Drugs 3/2011 Go to the issue

PHASE III STUDIES

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

PRECLINICAL STUDIES

Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan

PRECLINICAL STUDIES

Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents

PHASE II STUDIES

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

PRECLINICAL STUDIES

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

PHASE I STUDIES

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits